Laurent van Lerberghe

AQYLA BioVentures is a TechBio venture studio that discovers its own drug targets and builds biotech companies around them. We validate biology before deploying capital — using human disease models, causal BioML, and ChemAI — then launch SpinCos we fully own until Series A. Our first SpinCo, hit its first milestone in six months. Were scaling to five SpinCos by 2030. Website under construction, coming soon !

The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust. Headquartered in France, in the United States and in Canada, the Qynapse team, with our world-renowned team of scientific and clinical partners, is wholly dedicated to aspiring to bring the entire neuroscience community and their patients the clearest, most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimers disease, multiple sclerosis and Parkinson’s disease. We are constantly evolving, refining and testing our FDA-cleared and CE-marked neuroimaging software platform, QyScore®, which is powered by proprietary Artificial Intelligence, to provide physicians, pharma researchers and payers a reliable layer of precision when reading an MRI scan. QyPredict®, our predictive research-use-only platform powered by machine learning algorithms, is being designed to transform what we know about CNS disease trajectory, with the potential to dramatically increase the likelihood of a successful clinical trial. Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.

En rendant les parents acteurs de leur santé et celle de leur famille, nous créons un futur en meilleure santé.

Real-World Data you can trust, at scale. EHR-derived insights from a federated hospital network. High-quality, validated, cNLP-enriched medical data, supported by a secure European infrastructure.

WhiteLab Genomics is a TechBio company dedicated to unleashing the full power of genomic medicine with Artificial Intelligence. Founded in 2019 and backed by Y Combinator and the French Tech 2030 program, WhiteLab operates at the intersection of AI, computational biology, and structural biology, with offices in Paris, Boston, and Montréal. WhiteLab’s proprietary AI platform enables the rational design and optimization of delivery systems including viral and non-viral vectors, as well as RNA and DNA payloads. The company supports partners across a wide range of therapeutic areas, including but not limited to oncology, neurology, ophthalmology, auditory disorders, and rare diseases. WhiteLab’s mission is to unleash the potential of genomic medicine through advanced artificial intelligence, empowering scientists to design safer, more effective therapies from discovery through preclinical stages. WhiteLab collaborates with leading companies, including Sanofi, Cytiva and Debiopharm, and benefits from a strong network of top-tier academic partners such as the Brain Institute (ICM), the Vision Institute, the University of Massachusetts, and Genethon.

Découvrez la première plateforme entre patient(e)s et professionnel(le)s dédiée à l’amélioration des parcours de soins, de la fertilité à la maternité.

Butterfly Therapeutics est une entreprise innovante qui se consacre au développement et au déploiement de thérapies numériques. Des solutions protocolisées à l’efficacité cliniquement prouvée pour la gestion et le traitement de la douleur, au-delà de la chimie. #BlissDTx est utilisée en complément ou en substitution des produits pharmacologiques et des gaz médicaux traditionnels lors de gestes médicaux douloureux et de chirurgies. #Endocare est utilisée pour le traitement des douleurs chroniques telles que celles liées à l’endométriose.

Monka, expert de laccompagnement des aidants familiaux. Être confronté à la maladie ou à la perte d’autonomie d’un proche est une terrible épreuve à laquelle beaucoup d’entre nous devront un jour faire face. C’est pour que vous soyez soutenu, pour que vous puissiez disposer du chaînon manquant de confiance entre votre proche, vous et l’ensemble des interlocuteurs impliqués dans sa santé et à son service (médecins, infirmiers libéraux, services à la personne, institutions, etc) que Monka a été créé.

AQYLA BioVentures is a TechBio venture studio that discovers its own drug targets and builds biotech companies around them. We validate biology before deploying capital — using human disease models, causal BioML, and ChemAI — then launch SpinCos we fully own until Series A. Our first SpinCo, hit its first milestone in six months. Were scaling to five SpinCos by 2030. Website under construction, coming soon !

Were hiring worldwide! https://wandercraft.welcomekit.co/ At Wandercraft, we believe movement is freedom. Since 2012, our mission has been simple but bold: restore mobility where it’s been lost, and expand what’s possible with robotics that move like people do. We see robotics as the ultimate partners—machines that can do what humans cannot, or should not, do. That means giving back the ability to walk to someone with a spinal cord injury, or stepping in on a factory floor where work is too heavy, repetitive, or hazardous. We pioneered the world’s first self-balancing exoskeleton—technology that doesn’t rely on crutches or walkers, but lets people stand and walk freely. Today, our work goes beyond healthcare. From rehabilitation centers to factory floors, and soon into homes and communities, we’re shaping a future where humans and robots move forward together. Our technology, powered by physical AI and 30+ patents, is life-tested in the most demanding environments: real people, real steps, real work. Meet our devices: Atalante X – A self-balancing exoskeleton enabling hundreds of patients with mobility disabilities to take over 1 million steps per month in 100+ leading hospitals and research centers worldwide. It is designed to promote upright posture, cardiovascular health, neuroplasticity, and—most importantly—upright independence. Eve – The world’s first self-balancing exoskeleton for personal use. Designed for daily life, Eve enables individuals with severe mobility impairments to walk hands-free at home and outdoors. Currently in U.S. clinical trials, Eve is expected to launch in 2026. Calvin-40 – Our first industrial humanoid robot. Autonomous and voice-operated, Calvin-40 is built to take on physically demanding or hazardous tasks in non-ergonomic environments. Based on the same platform as our exoskeletons, Calvin is already hard at work with Renault Group and more.

Hexoskin offers a SaaS platform for digital biomarker development & AI-based diagnostics, based on a unique biometric shirt. The Hexoskins Connected Health Platform is an end-to-end system that offers advanced health data analytics, clinical protocol management, and body-worn sensors. Our open platform enables 3rd party support & interoperability. Hexoskins 100% washable smart clothing capture body metrics including heart rate, breathing rate, and activity. The Hexoskin sensors offer an easy and more natural way of regularly capturing precise data in daily activities. Hexoskin apps are available for iOS & Android devices, and smartwatches. Hexoskin is also the only clinically validated system that allows ECG cardiac monitoring with lung function and activity monitoring. Hexoskin is also a cost-effective and non-invasive solution for long-term monitoring of patients and subject for healthcare, clinical research & development, sports & fitness, aerospace, space, defense & first responders. The system is designed to reduce the frequency of travel and allow remote communication between patients, study volunteers, caregivers, and researchers

The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust. Headquartered in France, in the United States and in Canada, the Qynapse team, with our world-renowned team of scientific and clinical partners, is wholly dedicated to aspiring to bring the entire neuroscience community and their patients the clearest, most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimers disease, multiple sclerosis and Parkinson’s disease. We are constantly evolving, refining and testing our FDA-cleared and CE-marked neuroimaging software platform, QyScore®, which is powered by proprietary Artificial Intelligence, to provide physicians, pharma researchers and payers a reliable layer of precision when reading an MRI scan. QyPredict®, our predictive research-use-only platform powered by machine learning algorithms, is being designed to transform what we know about CNS disease trajectory, with the potential to dramatically increase the likelihood of a successful clinical trial. Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.

En rendant les parents acteurs de leur santé et celle de leur famille, nous créons un futur en meilleure santé.